Meeting
2015 ASCO Annual Meeting
Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in moderately emetogenic therapy (MEC).
Authors
Paul Joseph Hesketh
Lahey Hosp and Med Ctr, Burlington, MA
Paul Joseph Hesketh , Lee Steven Schwartzberg , Manuel R. Modiano , Sujata Arora , Allen Poma , Ian D. Schnadig
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Patient and Survivor Care
Track
Patient and Survivor Care
Sub Track
Symptom Management/Supportive Care
Clinical Trial Registration Number
NCT01500226
Citation
J Clin Oncol 33, 2015 (suppl; abstr 9622)
DOI
10.1200/jco.2015.33.15_suppl.9622
Abstract #
9622
Poster Bd #
281
Abstract Disclosures
Similar Posters
Poster
2015 Palliative and Supportive Care in Oncology Symposium
Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in non–anthracycline/cyclophosphamide (AC)-based moderately emetogenic therapy (MEC).
First Author: Daniel Powers
Poster
2016 Palliative and Supportive Care in Oncology Symposium
Rolapitant for the prevention of nausea in patients receiving moderately or highly emetogenic chemotherapy.
First Author: Rudolph M. Navari
Poster
2015 ASCO Annual Meeting
Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients (pts) receiving anthracycline-cyclophosphamide (AC)-based chemotherapy.
First Author: Ian D. Schnadig
Poster
2014 ASCO Annual Meeting
Safety of rolapitant, a novel NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic chemotherapy (MEC or HEC).
First Author: Laszlo Urban